The AIM- and Nasdaq-listed biopharma presented three posters at the American Society for Microbiology (ASM) Microbe 2019 meeting over the weekend.
The first presentation focused on dosage, with data showing that the 80mg fixed doses given to patients in the most recent REVIVE phase III trial were more efficacious than the weight-based doses given in earlier studies.
“The fixed dose regimen may help reduce the resources required in hospitals, since dosage adjustment by clinicians is avoided, and overall treatment costs may be lower, especially in patients with obesity or renal impairment,” said Motif.
A second poster highlighted the diverse patient population in the REVIVE and earlier ASSIST phase III studies.
In total, 1,093 patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) were treated with icplarim in the studies, with older patients and those with co-morbidities such as obesity, diabetes and renal impairment were “well-represented”.
In the REVIVE and ASSIST trials, respectively: 12% and 16% of patients treated with iclaprim were 65 or older; 15% and 8% were obese; 9% and 12% had diabetes; and 15% and 41% had renal impairment.
Antibiotic resistance a major global issue
In the third poster, Motif showed off iclaprim’s “potent activity” against various Gram-positive multi-drug resistant streptococci – the bacteria that can cause disorders such as pneumonia.
Streptococci is known for its resistance to azithromycin, clindamycin and tetracycline – three of the most common antibiotics currently used to fight bacterial infections.
“Given the growing public health concern about antibiotic resistance, it is important to continue to monitor the activity of iclaprim against these bacteria,” Motif added.